- Home
- EU vs PHAR Comparison
EU vs PHAR Comparison
Compare EU & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EU
- PHAR
- Stock Information
- Founded
- EU 2009
- PHAR 1988
- Country
- EU United States
- PHAR Netherlands
- Employees
- EU N/A
- PHAR N/A
- Industry
- EU Other Metals and Minerals
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- EU Basic Materials
- PHAR Health Care
- Exchange
- EU Nasdaq
- PHAR Nasdaq
- Market Cap
- EU 445.3M
- PHAR 1.0B
- IPO Year
- EU N/A
- PHAR N/A
- Fundamental
- Price
- EU $2.51
- PHAR $14.27
- Analyst Decision
- EU Strong Buy
- PHAR Strong Buy
- Analyst Count
- EU 1
- PHAR 3
- Target Price
- EU $4.00
- PHAR $30.00
- AVG Volume (30 Days)
- EU 5.0M
- PHAR 12.8K
- Earning Date
- EU 11-13-2025
- PHAR 10-23-2025
- Dividend Yield
- EU N/A
- PHAR N/A
- EPS Growth
- EU N/A
- PHAR N/A
- EPS
- EU N/A
- PHAR N/A
- Revenue
- EU $44,524,000.00
- PHAR $339,836,000.00
- Revenue This Year
- EU $33.35
- PHAR $16.63
- Revenue Next Year
- EU $112.45
- PHAR $6.77
- P/E Ratio
- EU N/A
- PHAR N/A
- Revenue Growth
- EU N/A
- PHAR 22.44
- 52 Week Low
- EU $1.01
- PHAR $7.31
- 52 Week High
- EU $4.44
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- EU 53.05
- PHAR 54.65
- Support Level
- EU $2.21
- PHAR $13.63
- Resistance Level
- EU $2.37
- PHAR $15.61
- Average True Range (ATR)
- EU 0.13
- PHAR 0.93
- MACD
- EU 0.03
- PHAR -0.13
- Stochastic Oscillator
- EU 78.95
- PHAR 35.98
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.